DiaMedica Therapeutics (NASDAQ:DMAC) Issues Quarterly Earnings Results, Misses Expectations By $0.01 EPS

DiaMedica Therapeutics (NASDAQ:DMAC) posted its earnings results on Monday. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.01), Zacks reports.

DiaMedica Therapeutics Price Performance

DMAC traded up $0.22 on Monday, hitting $5.99. The company had a trading volume of 106,512 shares, compared to its average volume of 69,604. The company’s fifty day moving average price is $5.95 and its 200 day moving average price is $5.08. DiaMedica Therapeutics has a 1-year low of $2.14 and a 1-year high of $6.82. The stock has a market cap of $256.14 million, a price-to-earnings ratio of -10.70 and a beta of 1.52.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.